Deregulation of BRCA1/2-directed miRNA and alteration of BRCA1/2 may share a common mechanism that affects the prognosis of ovarian cancer patients treated with platinum-based chemotherapy. This evidence concerns the gene BRCA1 and ovarian cancer.